Veligrotug Medicine 04 June 2024 Extended indication Graves ophthalmopathy Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Veligrotug Domain Chronic immune diseases Reason of inclusion New medicine (specialité) Main indication Eye disorders Extended indication Graves ophthalmopathy Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Viridian Portfolio holder Mechanism of action Unknown Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Insulin-like growth factor-I receptor antagonists Fabrikant: Viridian Therapeutics Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP No Submission date September 2025 Expected Registration October 2026 Orphan drug Yes Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks De fabrikant verwacht een registratieaanvraag in te dienen in mei 2024 Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Schildklier.nl Additional remarks Ongeveer 75.000 mensen hebben de ziekte van Graves, 20% daarvan heeft de oogaandoening Graves ophthalmopathie. Ongeveer 5% loopt het risico de oogziekte in ernstige vorm te ontwikkelen (3.750) Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks